Estrogen receptor testing of breast cancer in current clinical practice: What's the question?

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1797-1799

  Schnitt, Stuart J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHARCOAL; DEXTRAN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTIGEN; LETROZOLE; TAMOXIFEN; UNCLASSIFIED DRUG; TUMOR MARKER;

ANTIGEN DETECTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; TUMOR VOLUME; ARTICLE; BREAST TUMOR; CHEMISTRY; DRUG RESISTANCE; FEMALE; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33646373728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.0666     Document Type: Note

References (31)

1. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
2. Diaz LK, Sneige N: Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10-19, 2005
3. Elledge RM, Allred DC: Clinical aspects of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast (ed 3). Philadelphia, PA, Lippincott Williams and Wilkins, 2004, pp 603-617
4. Bezwoda WR, Esser JD, Dansey R, et al: The value of estrogen and progesterone receptor determinations in advanced breast cancer: Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 68:867-872, 1991
5. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
6. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996
7. Pertschuk LP, Feldman JG, Kim YD, et al: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77:2514-2519, 1996
8. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
9. Taylor CR: Paraffin section immunocytochemistry for estrogen receptor: The time has come. Cancer 77:2419-2422, 1996
10. Esteban JM, Ahn C, Mehta P, et al: Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 102:158-162, 1994
11. Lehr HA, Mankoff DA, Corwin D, et al: Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45:1559-1565, 1997
12. Layfield LJ, Saria E, Mooney EE, et al: Tissue heterogeneity of immunohistochemically detected estrogen receptor: Implications for image analysis quantification. Am J Clin Pathol 110:758-764, 1998
13. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000
14. Collins LC, Botero ML, Schnitt SJ: Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: An analysis of 825 cases. Am J Clin Pathol 123:16-20, 2005
15. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al: Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clin Pathol 123:21-27, 2005
16. Swanson PE, Schmidt RA: Beneath the surface of the mud: Part II. The dichotomization of continuous biologic variables by maximizing immunohistochemical method sensitivity. Am J Clin Pathol 123:9-12, 2005
17. Allred DC, Mohsin SK: ER expression is not bimodal in breast cancer. Am J Clin Pathol 124:474-475, 2005
18. Leong AS-Y, Milios J: Comparison of antibodies to estrogen and progesterone receptors and the influence of microwave-antigen retrieval. Appl Immunohistochem Mol Morphol 1:282-288, 1993
19. von Wasielewski R, Mengel M, Nolte M, et al: Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis Breast J 4:33-40, 1998
20. Santeusanio G, Mauriello A, Ventura L, et al: Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule. Appl Immunohistochem Mol Morphol 8:275-284, 2000
21. Rhodes A, Jasani B, Balaton AJ, et al: Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115:44-58, 2001
22. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86-92, 2003
23. Umemura S, Itoh J, Itoh H, et al: Immunohistochemical evaluation of hormone receptors in breast cancer: Which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 12:8-13, 2004
24. Vassallo J, Pinto GA, Alvarenga M, et al: Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol 12:177-182, 2004
25. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
26. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
27. Albain K, Barlow W, O'Malley F, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, estrogen (ER) and/or progesterone (PR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88.S20, 2004 (abstr 37)
28. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351-2817-2826, 2004
29. Viale G, Regan M, Dell'Orto P, et al: Central review of ER, PgR, and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 84:S13, 2005 (suppl 1)
30. Girault I, Lerebours F, Amarir S, et al: Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: Evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9:1259-1266, 2003
31. Keeton EK, Brown M: Coregulator expression and breast cancer: Improving the predictive power of estrogen receptor alpha. Clin Cancer Res 9:1229-1230, 2003